Bill > SB2308

This bill establishes a framework for creating a consortium to conduct clinical trials on ibogaine (a psychoactive substance) to seek U.S. Food and Drug Administration (FDA) approval for treating opioid use disorder, co-occurring substance use disorders, and other neurological or mental health conditions. The consortium must include a drug developer, an institution of higher education, and a hospital, with a lead institution responsible for administrative functions. The proposal requires detailed plans for clinical trials, including participant recruitment, safety protocols, and strategies for obtaining FDA approval. The bill outlines a comprehensive approach to securing funding, with the state potentially receiving at least 20% of revenue from intellectual property generated by the trials. The Health and Human Services Commission will select the consortium and enter into an interagency contract, with funds to be disbursed incrementally based on meeting specific objectives. If approved, the bill ensures medical supervision during ibogaine administration and requires quarterly reporting on trial progress. Notably, 25% of any state revenue generated would be earmarked for programs assisting veterans, highlighting a commitment to supporting those who have served. The bill is designed to facilitate research into a potentially promising treatment for substance use disorders while protecting state interests and ensuring rigorous medical oversight.

Health and Social Services

https://capitol.texas.gov/BillLookup/History.aspx?LegSess=89R&Bill=SB2308